Menu
Search
|

Menu

Close
X

Esperion Therapeutics Inc ESPR.OQ (NASDAQ Stock Exchange Global Market)

43.95 USD
-4.58 (-9.44%)
As of 4:00 PM EDT
chart
Previous Close 48.53
Open 48.17
Volume 549,218
3m Avg Volume 223,143
Today’s High 48.17
Today’s Low 43.91
52 Week High 79.30
52 Week Low 33.06
Shares Outstanding (mil) 26.82
Market Capitalization (mil) 1,301.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.93 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-7.542
FY17
-7.019
FY16
-3.325
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
--
8.91
Price to Book (MRQ)
vs sector
16.45
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
0.00
17.48
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-124.65
12.19
Return on Equity (TTM)
vs sector
-124.65
13.29

EXECUTIVE LEADERSHIP

Timothy Mayleben
President, Chief Executive Officer, Director, Since 2012
Salary: $557,500.00
Bonus: --
Richard Bartram
Chief Financial Officer and Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Narendra Lalwani
Executive Vice President - Research & Development, Since 2018
Salary: $390,000.00
Bonus: --
Nicole Vitullo
Independent Lead Director, Since 2015
Salary: --
Bonus: --
Roger Newton
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3891 Ranchero Dr Ste 150
ANN ARBOR   MI   48108-2837

Phone: +1734.8873903

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

SPONSORED STORIES